Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAPNASDAQ:AUTLNASDAQ:CRGXNASDAQ:DNTH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.24-1.1%$0.27$0.20▼$1.48$62.82M2.241.67 million shs297,252 shsAUTLAutolus Therapeutics$2.32+1.9%$1.74$1.11▼$5.00$616.12M1.761.58 million shs528,674 shsCRGXCARGO Therapeutics$4.24+2.8%$4.29$3.00▼$25.45$194.35M0.31573,989 shs76,859 shsDNTHDianthus Therapeutics$18.23-2.2%$19.09$13.37▼$32.27$588.21M1.37262,475 shs48,589 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics-2.16%-1.11%-9.55%-4.12%-75.41%AUTLAutolus Therapeutics-1.30%+3.17%+31.03%+61.70%-34.48%CRGXCARGO Therapeutics-1.67%-0.24%-2.83%0.00%-74.91%DNTHDianthus Therapeutics+5.67%+8.31%+6.95%+10.70%-28.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAPAdaptimmune Therapeutics2.1968 of 5 stars3.15.00.00.01.80.80.0AUTLAutolus Therapeutics2.8323 of 5 stars3.51.00.00.03.13.30.6CRGXCARGO Therapeutics2.5103 of 5 stars2.90.00.00.03.31.71.3DNTHDianthus Therapeutics1.6191 of 5 stars3.60.00.00.02.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 2.29Hold$1.35470.32% UpsideAUTLAutolus Therapeutics 3.00Buy$9.32301.03% UpsideCRGXCARGO Therapeutics 1.86Reduce$15.00254.19% UpsideDNTHDianthus Therapeutics 3.14Buy$53.00190.81% UpsideCurrent Analyst Ratings BreakdownLatest ADAP, DNTH, AUTL, and CRGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025ADAPAdaptimmune TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$1.50 ➝ $0.506/12/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/14/2025ADAPAdaptimmune TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.005/14/2025ADAPAdaptimmune TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.465/13/2025DNTHDianthus TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $50.005/13/2025DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.004/11/2025ADAPAdaptimmune TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/10/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/1/2025ADAPAdaptimmune TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $3.004/1/2025AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$178.03M0.35N/AN/A$0.05 per share4.74AUTLAutolus Therapeutics$9.01M68.64N/AN/A$1.61 per share1.44CRGXCARGO TherapeuticsN/AN/AN/AN/A$7.83 per shareN/ADNTHDianthus Therapeutics$6.24M93.93N/AN/A$11.91 per share1.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$70.81M-$0.27N/AN/AN/A-38.91%-163.73%-23.65%8/11/2025 (Estimated)AUTLAutolus Therapeutics-$220.66M-$0.88N/AN/AN/AN/A-52.82%-29.67%8/8/2025 (Estimated)CRGXCARGO Therapeutics-$167.50M-$4.62N/AN/AN/AN/A-45.93%-39.58%8/11/2025 (Estimated)DNTHDianthus Therapeutics-$84.97M-$2.88N/AN/AN/A-1,544.23%-29.26%-27.87%8/6/2025 (Estimated)Latest ADAP, DNTH, AUTL, and CRGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ADAPAdaptimmune Therapeutics-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million5/12/2025Q1 2025DNTHDianthus Therapeutics-$0.86-$0.82+$0.04-$0.82$0.81 million$1.16 million5/8/2025Q1 2025AUTLAutolus Therapeutics-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/AAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ACRGXCARGO TherapeuticsN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune Therapeutics4.242.021.79AUTLAutolus TherapeuticsN/A9.249.02CRGXCARGO TherapeuticsN/A6.306.30DNTHDianthus TherapeuticsN/A15.9815.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%AUTLAutolus Therapeutics72.83%CRGXCARGO Therapeutics93.16%DNTHDianthus Therapeutics47.53%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.44%AUTLAutolus Therapeutics25.70%CRGXCARGO Therapeutics2.92%DNTHDianthus Therapeutics16.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490265.05 million232.08 millionOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableCRGXCARGO Therapeutics11646.11 million44.76 millionN/ADNTHDianthus Therapeutics8032.16 million26.83 millionOptionableADAP, DNTH, AUTL, and CRGX HeadlinesRecent News About These CompaniesDNTH - Dianthus Therapeutics Inc Price vs Fair Value - MorningstarJune 26, 2025 | morningstar.comMDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 6% - What's Next?June 25, 2025 | marketbeat.comDNTH - Dianthus Therapeutics Inc Dividends - MorningstarJune 24, 2025 | morningstar.comMDNTH (NASDAQ:DNTH) Earnings Biotech Development Path Russell 1000June 23, 2025 | kalkinemedia.comKStifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% UpsideJune 23, 2025 | finance.yahoo.comWhat is Lifesci Capital's Estimate for DNTH Q2 Earnings?June 23, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $53.00 Average Price Target from BrokeragesJune 23, 2025 | americanbankingnews.comStifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% UpsideJune 21, 2025 | insidermonkey.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by BrokeragesJune 20, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.6% - Here's What HappenedJune 11, 2025 | marketbeat.comBrokers Offer Predictions for DNTH FY2026 EarningsJune 10, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Millennium Management LLCJune 3, 2025 | marketbeat.comDianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comDianthus Therapeutics appoints new board memberMay 24, 2025 | investing.comDianthus Therapeutics Appoints Simon Read, Ph.D., to Board of DirectorsMay 22, 2025 | globenewswire.com4DNTH : Breaking Down Dianthus Therapeutics: 5 Analysts Share Their ViewsMay 13, 2025 | benzinga.comDianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial ResultsMay 12, 2025 | globenewswire.comDianthus Therapeutics completes enrollment for MaGic trialMay 6, 2025 | investing.comDianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in SeptemberMay 5, 2025 | globenewswire.comDianthus Therapeutics to Participate in Two Upcoming Investor EventsApril 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADAP, DNTH, AUTL, and CRGX Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAP$0.24 0.00 (-1.13%) As of 12:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Autolus Therapeutics NASDAQ:AUTL$2.32 +0.04 (+1.93%) As of 12:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.CARGO Therapeutics NASDAQ:CRGX$4.24 +0.13 (+3.03%) As of 12:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Dianthus Therapeutics NASDAQ:DNTH$18.31 -0.32 (-1.72%) As of 12:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
